Prothena Stock Price, News & Analysis

Prothena Corporation (NASDAQ:PRTA) presented preclinical data on its dual Aβ/tau vaccine for Alzheimer’s and tandem C-terminal α-synuclein vaccine for Parkinson’s at the AD/PD 2022 Conference. The dual Aβ/tau vaccine demonstrated significant antibody generation, crucial for targeting amyloid plaques and tau tangles. The α-synuclein vaccine showed robust binding and inhibited the uptake of soluble α-synuclein. Prothena aims to file for an IND of the Alzheimer's vaccine in 2023, highlighting its commitment to developing innovative therapies for neurodegenerative diseases.

Prothena reported a Q4 2021 net loss of $33.2 million, having a full-year net income of $67.0 million. The firm generated $1.2 million in revenue for Q4 and $200.6 million for the full year, boosted by an $80 million payment from Bristol Myers Squibb and a $60 million milestone from Roche. Prothena's cash position stands at $580.4 million. The company has initiated several studies for Alzheimer's and Parkinson's treatments and expects a net cash use of $120 to $132 million in 2022. Financial guidance indicates a projected net loss of $154 to $170 million for the year.

Prothena Corporation plc (NASDAQ:PRTA) will announce its fourth quarter and full year 2021 financial results on February 17, 2022, after U.S. market close. The announcement will be followed by a live audio conference call at 4:30 PM ET, accessible via the company's website. Prothena is a biotech firm focused on therapeutics for neurodegenerative and rare diseases, leveraging expertise in protein dysregulation. Their pipeline includes candidates for AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases.

DUBLIN, Ireland, Nov. 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company, announced its senior management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:20 PM ET. A live webcast will be accessible on Prothena's investor relations site, with a replay available for at least 90 days post-event. Prothena focuses on investigational therapeutics targeting rare peripheral amyloid and neurodegenerative diseases, leveraging its expertise in protein dysregulation.

Prothena Corporation reported strong financial results for Q3 and the first nine months of 2021, achieving a net income of $109.2 million for Q3 compared to a loss of $30.6 million in Q3 2020. Total revenue reached $139.2 million, including $78.5 million from Bristol Myers Squibb and $60.7 million from Novo Nordisk. The company has $601.5 million in cash and no debt. Prothena continues to advance its pipeline, including the ongoing Phase 3 trial of birtamimab and collaborations with notable partners, positioning itself for further growth.

Prothena Corporation plc (NASDAQ:PRTA) will release its third quarter and first nine months of 2021 financial results on November 4, 2021, after U.S. market close. The company, focused on novel therapies for conditions related to protein dysregulation, will not hold a conference call following the release. Prothena continues to advance its pipeline targeting diseases such as AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's. This detailed focus on neurological dysfunction and misfolded proteins positions Prothena as a key player in addressing rare and neurodegenerative diseases.

Prothena Corporation plc (NASDAQ:PRTA) announced the hiring of two new employees, granting them options to purchase a total of 140,000 ordinary shares at an exercise price of $70.74. This price reflects the closing trading price on October 1, 2021. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant is part of Prothena's 2020 Employment Inducement Incentive Plan, approved by the board under Nasdaq guidelines.

Prothena Corporation (NASDAQ:PRTA) announced key executive changes aimed at bolstering its transition to a fully integrated biotechnology company targeting rare diseases. Tran B. Nguyen has been appointed Chief Strategy Officer while continuing his role as Chief Financial Officer. Brandon Smith steps in as Chief Operating Officer. These roles focus on enhancing Prothena's long-term growth strategy, operational capabilities, and pipeline development, aiding in its mission to commercialize novel therapeutics for conditions like AL amyloidosis and Alzheimer’s disease.

Prothena Corporation plc (NASDAQ:PRTA) announced the approval of a stock option grant to a new employee, allowing the purchase of 75,000 ordinary shares at an exercise price of $69.88. This is based on the closing trading price from September 1, 2021. The option will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This grant aligns with Prothena's 2020 Employment Inducement Incentive Plan.